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Background and Purpose: To evaluate the feasibility and heart-sparing ability of the voluntary 
breath-hold (VBH) technique in a multicentre setting. 
Material and Methods: Patients were recruited from 10 UK centres. Following surgery for early left 
breast cancer, patients with any heart inside the 50% isodose from a standard free-breathing 
tangential field treatment plan underwent a second planning-CT scan using the VBH technique. A 
separate treatment plan was prepared on the VBH CT scan and used for treatment. Mean heart, left 
anterior descending coronary artery (LAD) and lung doses were calculated. Daily electronic portal 
imaging (EPI) was performed and scanning/treatment times were recorded. The primary endpoint 
was the percentage of patients achieving a reduction in mean heart dose with VBH. Population 
systematic (Σ) and random errors (σ) were estimated. Within-patient comparisons between 
techniques used Wilcoxon signed-rank tests. 
Results: 101 patients were recruited during 2014. Primary endpoint data was available for 93 
patients, 88 (95%) of whom achieved a reduction in mean heart dose with VBH. Mean cardiac doses 
(Gy) for free-breathing and VBH techniques respectively were: heart 1.8 and 1.1, LAD 12.1 and 5.4, 
maximum LAD 35.4 and 24.1 (all p<0.001). Population EPI-based displacement data showed Σ of 1.3-
1.9mm and σ 1.4-1.8mm. Median CT and treatment session times were 21 and 22 minutes 
respectively. 
Conclusions: The VBH technique is confirmed as effective in sparing heart tissue and feasible in a 
multicentre setting.   
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Breast radiotherapy forms an integral part of many women’s breast cancer treatment, halving the 
risk of breast cancer recurrence and reducing breast cancer mortality [1, 2]. Breast radiotherapy is, 
however, associated with an increase in cardiac mortality [3] and morbidity [4], with patients 
receiving left breast radiotherapy particularly at risk [5] due to the proximity of the heart to 
tangential fields. Although mean cardiac doses from breast radiotherapy have reduced substantially 
since the 1980s [6], the linear relationship between the risk of cardiac events and mean heart dose 
and absence of a lower dose threshold [7] mean that reducing heart dose in breast radiotherapy 
remains a priority. Heart-sparing breast radiotherapy techniques, including deep inspiratory breath-
hold (DIBH), have been shown to be capable of reducing heart doses by around 50% [8-12]. 
An audit of UK breast radiotherapy practice by the Royal College of Radiologists in 2012 [Dr Imogen 
Locke, personal communication] found that, for 49% of patients with ‘heart in the field’, no cardiac-
sparing technique was used. In the majority of the remainder, multileaf collimation was used but, as 
demonstrated previously [13], this technique risks compromising target tissue coverage. Only 4% of 
centres used a DIBH technique. This low usage of heart-sparing radiotherapy was thought in part to 
reflect the fact that commercially-available systems are expensive to purchase and maintain. In 
order to overcome resource limitations, Stage IA of the UK HeartSpare Study evaluated an 
equipment-free voluntary breath-hold technique (VBH) using skin surface marks as fiducials, and 
demonstrated that this technique was comparable to treatment with a commercially-available 
system in terms of cardiac sparing and reproducibility [14]. Although the results from this single 
centre study were promising, further evaluation was required to establish the VBH technique as 
heart-sparing and feasible in other people’s hands. This non-randomised study therefore evaluated 
the heart-sparing ability and feasibility (i.e. reproducibility of set up and scanning/treatment times) 
of the VBH technique in a national multicentre setting. 
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Material and Methods 
This study was approved by Research and Development and Research Ethics Committees (ISRCTN 
62239447). Ten UK centres were selected, all of whom had satisfied the requirements of the UK 
National Cancer Research Institute (NCRI) FAST-Forward trial quality assurance programme, 
although participation in FAST-Forward was not a prerequisite to patient participation. Centres were 
selected on the basis of their FAST-Forward recruitment record and/or active participation in VBH 
technique development. In order to facilitate implementation at participating centres, all centres 
were invited to attend a training day. Centres were also provided with a technical video of the VBH 
technique in order to enhance local training and implementation. Skeleton work instructions were 
provided and each centre’s work instructions were reviewed by the trials team. All centres were 
required to submit recent electronic portal imaging (EPI) displacement data for ten consecutive left 
breast radiotherapy patients treated at their centre using standard free-breathing tangential field 
radiotherapy (minimum of five images per beam). Approval for study participation was granted 
locally at each centre.  
All participants underwent left breast conserving surgery or mastectomy for early stage invasive 
ductal or lobular carcinoma (pT1-3b N0-1 M0) or ductal carcinoma in situ (DCIS) and were 
recommended adjuvant radiotherapy to the whole breast or chest wall without nodal irradiation (+/- 
tumour bed boost). Women whose free-breathing planning-CT scan demonstrated the presence of 
any heart tissue within tangential radiotherapy fields placed according to standard anatomical 
borders (i.e. any heart within the 50% isodose) were approached. Patients were treated at 10 UK 
radiotherapy centres. This prospective study was not randomised. 
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Patient positioning and image acquisition 
Radiotherapy planning-CT scanning was performed in accordance with the FAST-Forward trial 
protocol [15]. The method for CT scanning using the VBH technique has been described previously 
[16]. All patients received training in the VBH technique prior to CT scanning [16]. For VBH planning-
CT scans, patients were aligned on the CT couch using markers (tattoos) placed during their previous 
free-breathing planning-CT scan.  
The time taken to complete each CT-planning session was recorded. After both scans were 
completed, patients and radiographers were asked to complete validated questionnaires [17] (see 
supplementary figures S1 and S2). 
 
Target and organ-at-risk delineation 
Target tissue and organs-at-risk (heart, lungs) were delineated in accordance with the FAST-Forward 
trial protocol on both free-breathing and VBH planning-CT scans. Either volume-based or field-based 
target outlining was performed, according to centre preference. To ensure consistency, the 
differences between target tissue PTVs for free breathing and VBH volumes were constrained to be 
no greater than 10%.  The left anterior descending coronary artery (LAD) was also outlined, as 
described previously [18].  
 
Radiotherapy planning 
Computer planning was performed on 3D datasets, and corrections for tissue heterogeneity were 
applied. Tangential fields were used to encompass the PTV, minimising dose to the ipsilateral lung 
and heart. Plans were prepared such that ≥90% of whole breast/chest wall PTV was covered by the 
95% isodose (V95% ≥90%), V105% ≤7%, V107% ≤2% and maximum point dose (Dmax) was ≤110%. 
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Dose constraints were applied for heart and ipsilateral lung. For heart, V25% ≤5% and V5% ≤30% and 
for ipsilateral lung V30% ≤17%. The prescription dose was 40.05Gy in 15 fractions over 3 weeks, 
except for patients randomised to a test arm of FAST-Forward for whom the prescribed dose was 
26/27Gy in 5 fractions over 1 week. Treatment technique and prescription dose were not specified 
for boost treatments, and no study data for this portion of a patient’s treatment was collected. 
Mean heart, LAD, ipsilateral and whole lung and maximum LAD (LADmax) doses were estimated for 
both free-breathing and VBH treatment plans. Dosimetric data was collected directly from 
participating centres’ computer planning systems. 
 
Radiotherapy delivery 
Patients were treated using the VBH technique, although free-breathing treatment (using the free-
breathing treatment plan) could be used at the discretion of the attending clinician (for example if a 
patient was unable to tolerate breath-hold on treatment). The VBH treatment technique for Elekta 
systems (Elekta, Crawley, UK) has been described previously [16]. For Varian systems, in-room lasers 
were used instead of light fields, because on Varian systems light fields switch off once the 
treatment beam is switched on. Treatment verification and corrections were performed according 
the FAST-Forward trial protocol [15]. For study reporting purposes, megavoltage EPI for both 
tangential fields was acquired daily and setup errors measured. 
Times at which patients mounted/dismounted the couch and at which the radiotherapy beam was 
switched on and off were recorded for every fraction. Patients and radiographers were asked to 
complete validated questionnaires recording comfort and satisfaction with the VBH technique on 
fractions 1 and 4 [17]. 
 




Using the Fleming A’Hern single stage procedure [19], a sample size of 33 patients was estimated to 
provide 90% power to detect if at least 75% of patients achieve a reduction in mean heart dose (Gy) 
with VBH compared with free-breathing, and exclude if this is less than 50% of patients (assuming a 
significance level of 0.05). It was envisaged that there may be a ‘learning curve’ with implementation 
of this technique at participating centres. In view of this, the first 5 patients recruited at each centre 
were included in a sensitivity analysis. Allowing for an additional 10% drop-out rate, the estimated 
sample size was 90 patients.  
Dose-volume histogram (DVH) data was used to determine the percentage of patients in whom a 
reduction in mean heart dose (Gy) was achieved with VBH and was compared between the two 
techniques (VBH and free-breathing) within individuals using Wilcoxon signed rank tests as the data 
was not normally distributed.  
EPI displacements were analysed in the (u,v)-plane for each patient (v-direction parallel to 
craniocaudal axis and u-direction perpendicular to this) [20], and population mean displacement 
(M), systematic (Σ) and random (σ) errors were estimated using the method described by van Herk 
[21]. 
Patient comfort and acceptability questionnaires for the VBH technique (see supplementary figures 
S1 and S2) were summarised as patient comfort scores (PCS) ranging from 0 (least comfortable) to 9 
(most comfortable). Radiographer satisfaction questionnaires were summarised as radiographer 
satisfaction scores (RSS) ranging from 0 (most satisfactory) to 9 (least satisfactory). Scores were 
calculated at each time-point (CT, first and fourth fractions). 
Statistical analyses were performed using SPSS Statistics Version 21 (IBM, Portsmouth, UK). 
 




101 patients were recruited from 10 UK centres between January and October 2014. Primary 
endpoint data was available for 93 (92%) patients and 88 (87%) patients completed treatment with 
VBH (see supplementary figure S3). The median age of patients recruited was 56 years (range 27-78). 
80 (79%) patients underwent breast conserving surgery, 11 (11%) patients underwent mastectomy 
(+/- reconstruction) and operation data was missing for 10 (10%) patients. 
Initial analysis demonstrated that dosimetric, reproducibility and timing data for the first five 
‘learning curve’ patients treated at each centre were comparable to patients treated subsequently 
(see supplementary tables S1-3). As such, data for the whole population were analysed together and 
are presented here.  
88/93 (95%) patients achieved a reduction in mean heart dose on their VBH radiotherapy treatment 
plan compared to their free-breathing treatment plan (mean reduction in dose 41%, p<0.001).  Two 
(2%) patients were withdrawn before dosimetric analysis on the basis that no difference in heart 
position was seen when visually comparing their free-breathing and VBH planning-CT scans. In a 
further two (2%) patients there was no difference in mean heart dose between the free-breathing 
and VBH treatment plans, and in one patient mean heart dose was less with free-breathing than 
VBH. Mean LAD and LADmax doses were reduced with VBH by 55% and 32% respectively (both 
p<0.001). No significant difference in mean lung doses was found between the two techniques. 
Mean normal tissue doses for free-breathing and VBH techniques are shown in Tables 1 (whole 
population) and S4 (grouped by centre). 
EPI displacement data are given in Tables 2 (whole population) and S5 (grouped by centre). The 
range of Σ and σ across centres was 0.3-2.6mm and 1.0-3.2mm respectively. One centre detected a 
systematic error in the superior-inferior direction during the course of the study. This was 
investigated by the trial management team together with the centre in question, and found to be 
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due to an incorrect setup procedure. On review, the error was found not to be of clinical significance 
and the centre’s setup procedure was corrected. 
Median patient comfort scores (range) [interquartile range] were 8 (2-9) [6-9], 8 (2-9) [6-9] and 9 (0-
9) [6-9] at CT-planning, fraction 1 and fraction 4 respectively (where 0 is least comfortable and 9 is 
most comfortable). Median radiographer satisfaction scores were 2 (0-9) [1-4], 1 (0-9) [0-3] and 1 (0-
9) [0-3] at CT-planning, fraction 1 and fraction 4 respectively (where 0 is most satisfactory and 9 is 
least satisfactory). Supplementary table S6 shows questionnaire results grouped by centre. 
The median CT-planning session time was 21 minutes, and was under 30 minutes in 9 out of 10 
centres. The median treatment session time over a treatment course was 22 minutes (see Figure 1), 
with patient setup accounting for 55% and treatment delivery accounting for 36% of this time. 
Median treatment session times were under 25 minutes for all centres (see supplementary table S7). 
 
Discussion 
This non-randomised study demonstrated that implementation of the VBH technique in a 
multicentre setting was both heart-sparing and feasible. The technique was reproducible across 
centres, acceptable to patients and radiographers and deliverable in treatment sessions of just over 
20 minutes. 
Mean heart dose was reduced with VBH in 95% of patients, well in excess of the 75% threshold set. 
VBH reduced all cardiac dose parameters measured, and the relative reductions seen are consistent 
with published literature [8-12].  
This study detected no significant difference between mean lung doses for free-breathing and VBH 
techniques. Published data suggest that DIBH techniques, although increasing absolute lung volume 
irradiated, tend to decrease fractional lung volume irradiated such that mean lung doses are 
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reported as 4-24% lower than with free-breathing techniques [8, 10-12, 22]. However, the relative 
reduction in lung dose in the largest of these studies (n=53) was also the lowest (4%) and was not 
statistically significant [11], suggesting that there may in fact be little difference in lung dose 
between free-breathing and DIBH techniques.  
The EPI-based population systematic and random errors in this study were small and consistent 
across participating centres. The errors were in line with those reported previously using VBH [14, 
23] and are well within values recommended for breast radiotherapy [24]. However, one centre did 
detect a systematic error during the course of study participation. The cause of this error was an 
incorrect treatment setup procedure, specifically not setting the isocentre to the midline tattoo in 
breath-hold. This is a vital step in the setup procedure, but easy to overlook if staff are not familiar 
with DIBH techniques. As a result of this error, all treatment plans of affected patients were 
reviewed and all were deemed to have received adequate tumour bed and breast coverage. In 
addition, the work instructions of all participating centres were reviewed for procedural errors. 
Although no clinical harm resulted, this incident highlights the need for internal auditing of setup 
procedures and reproducibility data when implementing novel radiotherapy techniques. 
This study used validated questionnaires to assess patient comfort and acceptability and 
radiographer satisfaction with the VBH technique, both important factors in the implementation of 
new radiotherapy techniques. VBH was viewed favourably by patients and radiographers alike in 
previous studies [14, 23]. However, in those studies it was compared to techniques which were 
viewed less favourably, and it is possible that this may have artificially enhanced the profile of VBH. 
However, the median questionnaire scores, narrow interquartile ranges and consistency in scores 
across participating centres suggest that VBH is acceptable to both patients and radiographers in a 
multicentre setting.  
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Breast radiotherapy accounts for approximately 30% of all radiotherapy treatments within the UK 
National Health Service (NHS) [25]  such that new breast radiotherapy techniques need to be time-
efficient in order to be sustainable and avoid an unacceptable burden on healthcare resources. Data 
from this study suggest that VBH radiotherapy CT-planning sessions should fit comfortably into a 30-
minute slot. The majority (60%) of CT-planning session time was devoted to patient setup, which 
included patient training in the VBH technique. Although the median reported CT session time was 
20 minutes, these times did not include the application of tattoos, as this had already been 
performed at patients’ free-breathing planning-CT session. However, these pre-existing tattoos may 
have actually increased setup time as it was necessary to align tattoos with lasers prior to scanning 
in VBH. Overall, it is anticipated that VBH CT-planning sessions, including the marking of tattoos, will 
be achievable within a standard 30-minute slot.  
Median treatment session times show that just over 20 minutes is required for treatment. Around 
half of this time is taken up with patient setup, with about a third of the total time required for 
treatment delivery. Treatment delivery using VBH does take longer than a standard free-breathing 
technique because several (usually 4-6) breath-holds are required to deliver the treatment. 
Treatment session times are likely to reduce once centres feel comfortable enough with the 
technique not to perform daily online imaging. In addition, treatment session times can be expected 
to reduce with increasing experience at delivering VBH, as has been observed at our centre, where 
treatment times now average around 11 minutes [Steven Landeg, personal correspondence]. 
In addition to failing to meet eligibility criteria (n=1) and not reducing heart dose with VBH (n=5, 
discussed above), reasons for study withdrawal can be split into two subgroups: i) patient difficulty 
with breath-holding (n=6) and ii) technique limitations (n=2). Five patients were unable to maintain 
their breath-hold (one patient developed a chest infection during treatment) and one patient’s 
breath-holds were inconsistent. This represents a low failure rate (approximately 1 in 17 patients) 
and, although higher than seen at our centre, is likely to reduce further as centres become more 
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experienced at patient training. With regard to technique limitations, one patient required bolus for 
treatment. Bolus covering the whole chest wall is currently incompatible with VBH as it obscures the 
skin marks during treatment. Solutions to this problem are being explored and include using thinner 
bolus (such that skin marks are visible through the bolus) and customised bolus (cutting the bolus 
such that the skin marks remain visible). One patient required a customised shell to support breast 
tissue, precluding the use of DIBH. 
The data presented here suggest that VBH is both heart-sparing and feasible to implement in a 
multicentre setting. In line with other breath-holding techniques, VBH effectively halves the mean 
heart dose during left breast radiotherapy; reducing mean heart dose from 2Gy to 1Gy in a 50 year 
old woman with ≥1 cardiac risk factor can be expected to more than halve the absolute risk of a 
radiotherapy-induced acute coronary event by 80 years, from 1.1% to 0.5% [7]. This study has 
demonstrated in a multicentre setting that VBH is reproducible and acceptable to patients and 
radiographers, although some additional treatment time is likely to be required. It is anticipated that 
the results of this study will lead to VBH becoming a standard of care in the NHS for patients 
requiring heart-sparing breast radiotherapy. It is recommended, however, that centres 
implementing VBH audit their setup data at an early stage in order that systematic errors caused by 
inadequate/incorrect setup procedures may be identified and rectified.  
 
Conclusions 
The VBH technique is confirmed as effective in sparing heart tissue and feasible in a multicentre 
setting. 
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Mean normal tissue doses (Gy) for free-breathing and voluntary breath-hold (VBH) techniques with 95% 
confidence intervals in brackets. 
 Free-breathing VBH p 
Heart 1.79 (1.66-1.91) 1.04 (0.97-1.12) <0.001 
LAD 11.9 (10.8-13.1) 5.3 (4.5-6.1) <0.001 
LADmax 35.2 (33.4-37.1) 24.0 (20.8-27.1) <0.001 
Ipsilateral lung 3.9 (3.6-4.2) 4.0 (3.7-4.2) 0.762 
Whole lung 1.9 (1.8-2.1) 2.0 (1.9-2.1) 0.374 
 
  




Population mean displacement (M), systematic (Σ) and random (σ) translational errors (mm) for the voluntary 
breath-hold (VBH) technique measured by electronic portal imaging (EPI) and in the (u,v)-plane. 
  Right anterior oblique beam (RAO) Left posterior oblique beam (LPO) 
u-plane M 0.4 -0.2 
 Σ 1.9 1.7 
 σ 2.0 1.9 
v-plane M 0.3 0.1 
 Σ 1.3 1.4 
 σ 1.7 1.8 
 
 
